Last update Jan. 6, 2021

Valganciclovir Hydrochloride

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Prodrug derived from ganciclovir. It is rapidly converted to ganciclovir through first pass intestinal and hepatic metabolism.
Prescribed for the treatment of Cytomegalovirus (CMV) retinitis in patients with AIDS and for prevention of disease from CMV in organ transplant recipients that have received an organ from a donor that tested positive for CMV.
Administered orally twice a day.

We could not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.

Due to its pharmacokinetic data (Roche 2018, Aurovitas 2015) it is difficult to accurately predict whether excretion through breast milk occurs. While its low molecular weight and negligible protein binding would facilitate it, its high distribution volume would impede it.

It possesses a much superior bioavailability compared to ganciclovir and therefore ganciclovir should be preferred when breastfeeding.

It has been used in infants and newborns (Roche 2018).


See below the information of this related product:

Alternatives

  • Ganciclovir (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Letermovir (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Valganciclovir Hydrochloride in other languages or writings:

Group

Valganciclovir Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Valganciclovir Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 60 %
Molecular weight 391 daltons
Protein Binding 1 - 2 %
VD 0,68 l/Kg
pKa 7,6 -
Tmax 1 - 3 hours
T1/2 4 hours

References

  1. Roche. Valganciclovir. Drug Summary. 2018 Full text (in our servers)
  2. Aurovitas. Valganciclovir. Ficha técnica. 2015 Full text (in our servers)

Total visits

3,044

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM